International Stem Cell Corporation Announces Positive Interim Clinical Results For Parkinson’s Disease Clinical Trial – Clinical Leader
|
International Stem Cell Corporation Announces Positive Interim Clinical Results For Parkinson’s Disease Clinical Trial
Clinical Leader Carlsbad CA (GLOBE NEWSWIRE) – International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today the positive six months … |
|
Immunotherapy deserves cautious optimism
SBS Immunotherapy is set to transform the landscape of how cancer is treated in the next five to 10 years however Australians have been cautioned it won’t be the miracle cure for every patient. Immunotherapy drugs like pembrolizumab (Keytruda) and … |
|
— Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian Cancer
Nasdaq Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced the submission of its Phase I/II clinical trial protocol to the U.S. Food and Drug Administration (FDA) for GEN-1, the Company’s DNA-based immunotherapy for … |
|
CORRECTING and REPLACING — Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat …
GlobeNewswire (press release) Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced the submission of its Phase I/II clinical trial protocol to the U.S. Food and Drug Administration (FDA) for GEN-1, the Company’s DNA-based immunotherapy for … |